Grant: Discovery Grants Program - Individual
McGill University
$30,000.00
Tissue engineering an artificial salivary gland device
EF 2014-15
Résumé
Why should anyone wish to construct an artificial salivary gland (SG)? The answer lies in filling a clinical need for the 4,000 Canadians diagnosed each year with cancer of the head and neck. Worldwide, this amounts to 640,000 new patients yearly. These patients receive therapeutic irradiation as a treatment for their cancer. SGs in the field of radiation are severely damaged, resulting in a loss of salivary acinar cells, the principal site of fluid secretion (i.e. saliva). These patients experience considerable morbidity and discomfort such as dry mouth, difficulty swallowing, tooth decay, loss of taste to foods, and oro-pharyngeal infections/ ulcers. For many patients, there is currently no available adequate treatment. They cannot utilize existing pharmacological tools (such as saliva-stimulating drugs), which require the presence of some surviving epithelial tissue. Accordingly, we have been motivated to develop an orally implantable fluid secretory device for treating such patients. To date, a major hurdle in the fabrication of our device has been finding a suitable graft cells that can secrete water (saliva) and can be expanded readily for incorporation in the device. Our objectives for this proposal are to: 1) Build a three-dimensional (3-D) artificial SG prototype and test if it can move fluid unidirectionally; 2) Engineer human saliva-secreting cells and assess their capability to tissue assembly in 3-D gel environments (such as fibronectin gel, basement membrane extract gel, chondroitin sulfate and polyethylene glycol hydrogel); 3) Assess two methods to deliver engineered human saliva-secreting cells into mice with SGs damaged by irradiation: a) by direct injection into the glandular tissue, or b) by intra-ductal cannulation and infusing the cells under pressure. The impact of re-engineering epithelial cells to possess a fluid secretory function in the artificial SG device or in 3-D gels would be a key breakthrough for the many patients affected with dry mouth. It could offer to millions of patients worldwide, having reduced or no saliva output, effective treatment option. These include the potential for regeneration and repair of salivary acinar cells in adult glands, and the potential for these cells to be used in an implantable artificial SG device.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
327846-2011
Name nom
Tran, Simon
Department département
Dentistry, Faculty of
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2011
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
4
Nb partie
5
Application title
Tissue engineering an artificial salivary gland device
Keyword
NSERC
Application summary
Why should anyone wish to construct an artificial salivary gland (SG)? The answer lies in filling a clinical need for the 4,000 Canadians diagnosed each year with cancer of the head and neck. Worldwide, this amounts to 640,000 new patients yearly. These patients receive therapeutic irradiation as a treatment for their cancer. SGs in the field of radiation are severely damaged, resulting in a loss of salivary acinar cells, the principal site of fluid secretion (i.e. saliva). These patients experience considerable morbidity and discomfort such as dry mouth, difficulty swallowing, tooth decay, loss of taste to foods, and oro-pharyngeal infections/ ulcers. For many patients, there is currently no available adequate treatment. They cannot utilize existing pharmacological tools (such as saliva-stimulating drugs), which require the presence of some surviving epithelial tissue. Accordingly, we have been motivated to develop an orally implantable fluid secretory device for treating such patients. To date, a major hurdle in the fabrication of our device has been finding a suitable graft cells that can secrete water (saliva) and can be expanded readily for incorporation in the device. Our objectives for this proposal are to: 1) Build a three-dimensional (3-D) artificial SG prototype and test if it can move fluid unidirectionally; 2) Engineer human saliva-secreting cells and assess their capability to tissue assembly in 3-D gel environments (such as fibronectin gel, basement membrane extract gel, chondroitin sulfate and polyethylene glycol hydrogel); 3) Assess two methods to deliver engineered human saliva-secreting cells into mice with SGs damaged by irradiation: a) by direct injection into the glandular tissue, or b) by intra-ductal cannulation and infusing the cells under pressure. The impact of re-engineering epithelial cells to possess a fluid secretory function in the artificial SG device or in 3-D gels would be a key breakthrough for the many patients affected with dry mouth. It could offer to millions of patients worldwide, having reduced or no saliva output, effective treatment option. These include the potential for regeneration and repair of salivary acinar cells in adult glands, and the potential for these cells to be used in an implantable artificial SG device.